MAPT and Alzheimer disease: Taken together, our data suggest that the protective effect of the APOE-ε2 allele for developing clinical AD appears to be primarily linked to resistance against Aβ deposition [49] rather than tau pathology, and that the effect of the APOE-ε4 allele on tau burden is mostly secondary to the prominent effect on increased Aβ load.